

# INPLASY

## Impact of vaginal estriol on endometrial tissue - a systematic review

INPLASY202420035

doi: 10.37766/inplasy2024.2.0035

Received: 06 February 2024

Published: 07 February 2024

Kolokythas, A<sup>1</sup>; Vollrath, S<sup>2</sup>; Betschart, C<sup>3</sup>; Wunder, D<sup>4</sup>; Stute, P<sup>5</sup>.

### Corresponding author:

Argyrios Kolokythas

argy.kolokythas@gmail.com

### Author Affiliation:

University of Bern.

### ADMINISTRATIVE INFORMATION

**Support** - N/A.

**Review Stage at time of this submission** - Data extraction.

**Conflicts of interest** - The authors Petra Stute, Cornelia Betschart and Dorothea Wunder have been part of an interdisciplinary expert board funded by EFFIK SA. Argyrios Kolokythas and Sabrina Vollrath report no conflict of interest. The authors alone are responsible for the content and writing of the paper.

**INPLASY registration number:** INPLASY202420035

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 07 February 2024 and was last updated on 07 February 2024.

### INTRODUCTION

**Review question / Objective** Do local vaginal estriol products induce changed in endometrial tissue?

**Condition being studied** The aim of this review is to study whether the vaginal application of estriol has any effects on endometrial tissue and whether it increases the risk for endometrial hyperplasia or malignancies.

### METHODS

**Participant or population** Inclusion: postmenopausal women (natural, treatment-induced, or surgical menopause). Exclusion: route of application other than intravaginal, study types: other than the ones mentioned below.

**Intervention** Inclusion: intravaginal administration of estriol. Exclusion: other routes of estriol administration.

**Comparator** Inclusion: intravaginal administration of estriol of different dosage, intravaginal administration of estradiol, intravaginal administration of lubricant (placebo), no intravaginal administration of any product.

**Study designs to be included** RCTs, controlled studies, head-to-head comparisons, systematic reviews, meta-analyses, quasi-experimental studies (intervention/no control - pre-/post-studies).

**Eligibility criteria** No additional criteria.

---

**Information sources** MEDLINE; CINAHL; Embase; Cochrane Library; Web of Science; ClinicalTrials.gov.

**Main outcome(s)** sonographically thickened endometrium, need for biopsy, postmenopausal bleeding, endometrial hyperplasia, endometrial cancer

**Quality assessment / Risk of bias analysis** Randomization, blinding, inclusion and exclusion criteria, reporting of dropouts and explanation, intention to treat vs per protocol.

**Strategy of data synthesis** Descriptive analysis.

**Subgroup analysis** No subgroup analysis intended.

**Sensitivity analysis** No sensitivity analysis intended.

**Language restriction** None.

**Country(ies) involved** Switzerland.

**Keywords** menopause; GSM; endometrium; vaginal estriol; postmenopausal bleeding; hyperlasia.

**Contributions of each author**

Author 1 - Argyrios Kolokythas.  
Author 2 - Sabrina Vollrath  
Author 3 - Dorothea Wunder.  
Author 4 - Cornelia Betschart  
Author 5 - Petra Stute.